Nippon Shinyaku sets up China subsidiary

5 November 2021

Mid-sized Japanese drugmaker Nippon Shinyaku (TYO: 4516), which is focussed on rare disease and blood cancer treatments, has announced the setting up a subsidiary in China’s capital, Beijing.

The subsidiary, which is called Beijing Ai Nu Ai Shi, will act as a marketing authorization holder (MAH) to bring Nippon Shinyaku's drugs to China.

The Japanese pharma in June filed a new drug application (NDA) in China for Viltepso (viltolarsen), a treatment for the rare disease Duchenne muscular dystrophy. The company already has a trading office in Beijing, but only an MAH is allowed to conduct necessary practices such as filing IND applications in China, according to Chinese regulations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK